...
首页> 外文期刊>Japanese Journal of Pharmacology >Effects of acute and chronic administration of MCI-225, a new selective noradrenaline reuptake inhibitor with 5-HT3 receptor blocking action, on extracellular noradrenaline levels in the hypothalamus of stressed rats.
【24h】

Effects of acute and chronic administration of MCI-225, a new selective noradrenaline reuptake inhibitor with 5-HT3 receptor blocking action, on extracellular noradrenaline levels in the hypothalamus of stressed rats.

机译:急性和慢性给药MCI-225,一种具有5-HT3受体阻断作用的新型选择性去甲肾上腺素再摄取抑制剂,对应激大鼠下丘脑细胞外去甲肾上腺素水平的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

In the present study, we investigated the effects of acute and chronic systemic administration of MCI-225 (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine monohydrate hydrochloride), a newly-developed selective noradrenaline (NA) reuptake inhibitor with 5-HT3-receptor-blocking action, on extracellular NA levels in the hypothalamus of stressed and non-stressed rats by utilizing intracerebral microdialysis. Acute administration of MCI-225 (3 and 10 mg/kg, p.o.) significantly and dose-dependently increased extracellular NA levels in the hypothalamus in non-stressed rats. Footshock for 20 min also significantly increased NA levels in the hypothalamus of both groups of rats pretreated with vehicle and MCI-225. Although chronic administration of MCI-225 (3 or 10 mg/kg, p.o. for 14 days) did not alter the basal extracellular NA levels in the hypothalamus, the stress-induced increases in extracellular NA levels were significantly lower in rats chronically treated with MCI-225 (10 mg/kg) than those of rats pretreated with vehicle for the same period. The increase in extracellular NA levels induced by MCI-225 challenge (3 or 10 mg/kg, p.o.) were not different between rats chronically treated with MCI-225 or vehicle. These results suggest that MCI-225 enhances extracellular NA levels in the hypothalamus in both non-stressed and stressed rats by inhibiting NA uptake and that chronic systemic administration of MCI-225 did not alter basal extracellular NA levels, but reduced the increase in NA release caused by footshock stress. These data suggest the possibility that MCI-225 might possess anxiolytic and/or antidepressant properties.
机译:在本研究中,我们调查了急性和慢性全身给药MCI-225(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-d]嘧啶一水合物盐酸盐的影响)是一种新开发的具有5-HT3-受体阻滞作用的选择性去甲肾上腺素(NA)再摄取抑制剂,通过利用脑内微透析对应激和非应激大鼠下丘脑的细胞外NA水平产生影响。急性给予MCI-225(3和10 mg / kg,p.o.)可以显着且剂量依赖性地增加非应激大鼠下丘脑的细胞外NA水平。休克20分钟也显着增加了用媒介物和MCI-225预处理的两组大鼠下丘脑的NA水平。尽管长期服用MCI-225(3或10 mg / kg,口服14天)不会改变下丘脑的基础细胞外NA水平,但长期用MCI治疗的大鼠在应激诱导下的细胞外NA水平升高明显降低-225(10 mg / kg)比同期用媒介物预处理的大鼠要高。在用MCI-225或媒介长期治疗的大鼠之间,由MCI-225激发(3或10 mg / kg,p.o。)诱导的细胞外NA水平的增加没有差异。这些结果表明,MCI-225通过抑制NA摄取而提高了非应激和应激大鼠下丘脑的细胞外NA水平,并且长期全身给药MCI-225不会改变基础细胞外NA水平,但减少了NA释放的增加触电引起的压力。这些数据表明MCI-225可能具有抗焦虑和/或抗抑郁特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号